Ambroxol vs placebo or no treatment: Incidence of RDS frequency in newborns
- Population
- women at risk of preterm birth
- Intervention
- Ambroxol
- Comparison
- placebo or no treatment
- Outcome
- Incidence of RDS frequency in newborns
Ambroxol showed no clear difference in incidence of RDS frequency in newborns compared with placebo or no treatment (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Ambroxol vs placebo or no treatment Incidence of RDS frequency in newborns · pregnant women at risk of preterm birth for preventing neonatal respiratory distress syndrome Ambroxol showed no clear difference in incidence of RDS frequency in newborns compared with placebo or no treatment (low certainty). Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome (2014) · Cochrane Headline outcomes only | RR 0.74 [0.46, 1.2] | 2 studies · 204 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Ambroxol vs corticosteroid (betamethasone) · women at risk of preterm birth · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.